FORM 4	
--------	--

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
Zhang Jack Y.	Amphastar Pharmaceuticals, Inc. [	
	AMPH ]	_X_Director _X_10% Owner
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X_Officer (give title below) Other (specify below)
		CEO & Chief Scientific Officer
C/O AMPHASTAR	3/6/2023	
PHARMACEUTICALS, INC., 11570		
6TH STREET		
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)		Form filed by One Reporting Person X Form filed by More than One Reporting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

		-	· I ·	. ' '	,	·			
			de	or Dispos	ed of (D)		Following Reported Transaction(s)	Form: Direct (D)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price		(I) (Instr. 4)	(Instr. 4)
3/6/2023		A		81383 (1)	Α	\$0.00	2185526	D	
3/6/2023		Α		34301 <u>(1)</u>	Α	\$0.00	1532820		See footnote <mark>(</mark> 2
							6827679		See footnote (3
							5000		See footnote <mark>(</mark>
	2. Trans. Date 3/6/2023	2. Trans. Date 2A. Deemed Execution Date, if any 3/6/2023	2. Trans. Date 2A. Deemed Execution Date, if any Code 3/6/2023 A	2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code (Instr. 8) Code V 3/6/2023 A Code V	2. Trans. Date     2A. Deemed     3. Trans. Code     4. Securiti       Execution     Instr. 8)     9. Securiti     9. Securiti       Date, if any     Code     V     Amount       3/6/2023     A     81383 (1)	2. Trans. Date       2A. Deemed       3. Trans. Code       4. Securities Acquir         Date, if any       (Instr. 8)       4. Securities Acquir         Or Disposed of (D)       (Instr. 3, 4 and 5)         3/6/2023       A       81383 (1)	2. Trans. Date       2A. Deemed       3. Trans. Code       4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)         2. Trans. Date       2A. Deemed       (Instr. 8)       4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)         3/6/2023       A       81383 (1)       A       \$0.00	Execution Date, if any(Instr. 8)or Disposed of (D) (Instr. 3, 4 and 5)Following Reported Transaction(s) $23/6/2023$ AVAmount(A) or (D)Price $3/6/2023$ A81383 (1)A\$0.002185526 $3/6/2023$ A34301 (1)A\$0.001532820 $3/6/2023$ AIII6827679	2. Trans. Date Execution Date, if any3. Trans. Code (Instr. 8)4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)6. Ownership Form: Direct (D) or Indirect (I) (Instr. 3 and 4)3/6/2023A81383 (1) AA\$0.002185526D3/6/2023A34301 (1) CodeA\$0.001532820I

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			 					,,		ptions, conve				
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	 4. Trans. Code (Instr. 8)		5. Number of Derivative Secu Acquired (A) o Disposed of (D (Instr. 3, 4 and	urities r )	<ol> <li>Date Exer and Expirati</li> </ol>		7. Title and A Securities U: Derivative S (Instr. 3 and	nderlying ecurity	8. Price of Derivative Security (Instr. 5)	Securities Beneficially	Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security		Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			or Indirect	
Employee Stock Option (right to buy)	\$35.13	3/6/2023	А		171488		( <u>5)</u>	3/6/2033	Common Stock	171488	\$0	171488	D	
Employee Stock Option (right to buy)	\$35.13	3/6/2023	А		72278		<u>(5)</u>	3/6/2033	Common Stock	72278	\$0	72278		See footnote <sup>(2)</sup>

### **Explanation of Responses:**

- (1) The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 6, 2024.
- (2) The securities are held of record by Mary Z. Luo. The reporting persons are husband and wife.
- (3) The shares are held of record by Applied Physics & Chemistry Laboratories, Inc., of which the reporting persons and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.
- (4) The shares are held of record in an account for the benefit of the reporting persons' son. The reporting persons disclaim beneficial ownership of these shares, and the inclusion of these shares in this report should not be deemed an admission of beneficial ownership of any such shares for purposes of Section 16, or for any other purpose.
- (5) The shares subject to the option vest in four equal annual installments beginning on March 6, 2024.

## **Reporting Owners**

Reporting Owner Name / Address		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Zhang Jack Y.						

C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	Х	CEO & Chief Scientific Officer	
Luo Mary Z. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	X	X	CEO & Chief Scientific Officer	

#### Signatures

/s/ Eva Wen, by power of attorney for Jack Y. Zhang	3/8/2023
**Signature of Reporting Person	Date
/s/ Eva Wen, by power of attorney for Mary Z. Luo	3/8/2023
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.